Go Pro
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$144.74
-1.9%		$143.63
$109.66
▼
$157.29
$179.47B0.316.87 million shs4.80 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$37.31
-0.2%		$44.63
$35.12
▼
$64.16
$166.59B0.7717.07 million shs10.17 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$504.73
-0.4%		$519.58
$400.73
▼
$560.25
$128.10B0.281.38 million shs939,520 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.04%-1.46%-1.61%+12.36%+32.70%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.40%-3.14%-17.11%-25.79%-36.78%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-3.07%-2.99%-7.47%-4.03%+25.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$144.74
-1.9%		$143.63
$109.66
▼
$157.29
$179.47B0.316.87 million shs4.80 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$37.31
-0.2%		$44.63
$35.12
▼
$64.16
$166.59B0.7717.07 million shs10.17 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$504.73
-0.4%		$519.58
$400.73
▼
$560.25
$128.10B0.281.38 million shs939,520 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.04%-1.46%-1.61%+12.36%+32.70%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-1.40%-3.14%-17.11%-25.79%-36.78%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-3.07%-2.99%-7.47%-4.03%+25.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$158.789.97% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.07
Hold$102.85175.86% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.96
Moderate Buy$575.1314.20% Upside

Current Analyst Ratings Breakdown

Latest GILD, NVO, and VRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/29/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
9/28/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$585.00 ➝ $615.00
9/22/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cfra logo
Cfra
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell$38.00
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/21/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
9/21/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$594.00
9/14/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.08$10.14 per share14.24$18.23 per share7.92
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.56$4.61 per share8.09$6.58 per share5.67
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B10.65$16.93 per share29.75$73.57 per share6.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.63N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.099.1210.901.2435.36%58.61%20.91%11/4/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1829.3427.442.2935.00%23.09%16.72%11/2/2026 (Estimated)

Latest GILD, NVO, and VRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.12N/AN/AN/A$7.77 billionN/A
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.27%+3.04%N/A 10 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.822.20%+21.74%20.05%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest GILD, NVO, and VRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.24%9/15/20269/15/20269/29/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

CRISPR Therapeutics to Present Phase 1 Data on Zugo-cel in Refractory Systemic Sclerosis at ACR Convergence 2026
October 2 at 10:30 AM  |  quiverquant.comQ
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1 at 10:03 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-stock-falls-210006610.html
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
October 1 at 10:03 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-2-other-top-220722974.html
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
October 1 at 7:00 PM  |  zacks.comhttps://www.zacks.com/stock/news/2999228/vertex-pharmaceuticals-vrtx-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v2-2999228
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
October 1 at 5:02 PM  |  fool.comhttps://www.fool.com/coverage/better-buy/2026/10/01/axsome-therapeutics-vs-vertex-pharmaceuticals-which-biotech-stock-is-a-better-buy-in-2026/
The Top HealthTech Questions Landing on Our Desks
September 30 at 7:06 AM  |  etftrends.comE
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
September 29 at 8:30 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4950636-vertex-stock-still-too-much-emphasis-on-cf-supremacy-i-foresee-rating-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29 at 5:50 AM  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=f5a22054-2c3a-46c9-8d92-39aea9607e62
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
September 29 at 5:10 AM  |  fool.comhttps://www.fool.com/investing/2026/09/29/2-wall-street-analysts-think-vertex-may-soar/
2 Healthcare Stocks to Target This Week and 1 We Avoid
September 29 at 1:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/2-healthcare-stocks-target-week-103836911.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 29 at 1:24 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-vertex-pharmaceuticals-vrtx-kidney-003708108.html
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
September 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/could-vertex-pharmaceuticals-vrtxs-kidney-breakthrough-unlock-a-new-opportunity-for-maze-therapeutics-maze-1846012/
2 Healthcare Stocks That Just Delivered Great News for Investors
September 26, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/26/2-healthcare-stocks-that-just-delivered-great-news-for-investors/
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Envestnet Asset Management Inc.
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-envestnet-asset-management-inc-2026-09-25/
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-vrtx-increases-despite-205006588.html
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995473/vertex-pharmaceuticals-vrtx-increases-despite-market-slip-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2995473
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/4774298/vertex-pharmaceuticals-vrtx-gets-a-hold-from-canaccord-genuity/
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertexs-kidney-disease-pipeline-growth-142700227.html
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995249/will-vertex-s-kidney-disease-pipeline-be-a-new-growth-engine?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2995249
TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/td-cowen-adjusts-pt-vertex-095804034.html
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-vrtx-stock-could-24-032311578.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Novo Nordisk logo displayed in a laboratory setting with vials, an insulin pen, and a researcher in the background.
Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
By Thomas Hughes | September 23, 2026
Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$144.74 -2.76 (-1.87%)
Closing price 04:00 PM Eastern
Extended Trading
$144.75 +0.01 (+0.01%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$37.31 -0.09 (-0.24%)
Closing price 03:59 PM Eastern
Extended Trading
$37.31 0.00 (0.00%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$504.73 -2.01 (-0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$507.37 +2.64 (+0.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas